GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Sanofi
Sanofi is a French pharmaceutical giant with a diversified portfolio of drugs, vaccines, and consumer healthcare products. Its share price depends on the success of key drugs such as Dupixent and the ability of its R&D division to create new blockbusters.
Share prices of companies in the market segment - Pharma holding
Sanofi is a French pharmaceutical giant with segments in vaccines, specialty medicine, and consumer healthcare. We classify it as part of the Pharma Holdings sector, and the chart below shows the overall performance of the entire large drug manufacturing industry.
Broad Market Index - GURU.Markets
Sanofi is a French pharmaceutical giant with strong positions in vaccines, rare diseases, and consumer healthcare. Its scale makes it a key component of the GURU.Markets index. The chart below represents the entire market. See how Sanofi shares compare to the broader market.
Change in the price of a company, segment, and market as a whole per day
SNY - Daily change in the company's share price Sanofi
The daily price fluctuations for Sanofi, the French pharmaceutical giant, reflect its sensitivity to research results and market competition. While the graph of these fluctuations is unspectacular, it is an important component of the formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma holding
Sanofi is a major European pharmaceutical company. This chart shows the average daily volatility of the entire industry. Comparing it with SNY dynamics helps understand the extent to which its diversified drug portfolio and focus on vaccines make the company more or less exposed to industry risks.
Daily change in the price of a broad market stock, index - GURU.Markets
Sanofi is a French pharmaceutical giant. The pharmaceutical sector can be defensive, but breakthroughs and setbacks in drug development create their own volatility. The chart below shows the overall market dynamics, allowing you to assess how Sanofi fits into the global investment landscape.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Sanofi
Sanofi, the French pharmaceutical giant, has seen strong growth over the past year thanks to its blockbuster drug Dupixent. The company has also been actively working on its R&D pipeline. The chart below shows how investors assessed the strength of its key products and future prospects.
Annual dynamics of market capitalization of the market segment - Pharma holding
Sanofi, the French pharmaceutical giant, has a diversified portfolio of drugs and vaccines. The company is focusing on innovative drugs to offset the loss of patents on older blockbusters. The chart will show how successful its R&D strategy is compared to other major players in Big Pharma.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Sanofi is a diversified global pharmaceutical company. Its performance depends on the success of its broad portfolio of drugs and vaccines, as well as its ability to bring new drugs to market. While the sector is generally defensive, Sanofi shares reflect investors' faith in its research capabilities and future blockbusters.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Sanofi
The monthly price fluctuations of Sanofi, a major European pharmaceutical company, reflect the development and sales success of its key drugs. The chart's dynamics depend on news about clinical trials, particularly the blockbuster Dupixent, and the company's efforts to renew its portfolio through new developments and acquisitions.
Monthly dynamics of market capitalization of the market segment - Pharma holding
What you're looking at is the dynamics of the entire pharmaceutical sector. For Sanofi, one of the global giants, this is the backdrop. It shows how the company, while managing a portfolio of mature drugs, is seeking new sources of growth, particularly thanks to the success of its blockbuster Dupixent.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Sanofi is a French pharmaceutical giant with a diversified portfolio of drugs and vaccines. Like other large pharmaceutical companies, it is often considered a defensive asset. The chart below shows the overall market sentiment, which could favor Sanofi shares due to continued demand for its products.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Sanofi
Sanofi, the French pharmaceutical giant, sees its stock react weekly to news about clinical trials, particularly in immunology and rare diseases, as well as sales of its blockbuster drug Dupixent. The chart reflects investors' assessment of the company's ability to innovate its product portfolio.
Weekly dynamics of market capitalization of the market segment - Pharma holding
Sanofi, like other large pharmaceutical companies, often follows the mainstream. However, investors compare its product portfolio and R&D success to those of its competitors. The chart shows whether the market is rewarding its successes, such as with Dupixent, with a higher valuation than the industry average, or whether the company is lagging behind.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Sanofi is a French pharmaceutical giant. Big pharma stocks are traditionally considered "defensive" due to stable demand for their medications. This chart will help us see whether Sanofi's weekly fluctuations actually smooth out overall market volatility.
Market capitalization of the company, segment and market as a whole
SNY - Market capitalization of the company Sanofi
The Sanofi capitalization chart shows how the market values one of Europe's leading pharmaceutical giants. Its price dynamics reflect its success in drug development, particularly its blockbuster Dupixent for the treatment of atopic dermatitis and asthma. The company's valuation depends on its ability to expand its portfolio with new, successful drugs.
SNY - Share of the company's market capitalization Sanofi within the market segment - Pharma holding
Sanofi is a French pharmaceutical giant with strong market shares in vaccines, rare disease treatments, and over-the-counter medications. Its market capitalization reflects its diversified portfolio and global presence, providing the company with stability in the healthcare sector.
Market capitalization of the market segment - Pharma holding
The chart below shows the trillion-dollar value of the global pharmaceutical industry. Sanofi, a French giant and one of its pillars, has strong positions in vaccines, rare diseases, and consumer health. The dynamics of this market reflect a constant need for innovation, and Sanofi plays a key role in this process.
Market capitalization of all companies included in a broad market index - GURU.Markets
Sanofi is a French pharmaceutical giant with a diversified portfolio of drugs, vaccines, and consumer healthcare products. Its market capitalization reflects its global reach and business stability. The chart below shows the relative weight of traditional European pharmaceutical companies.
Book value capitalization of the company, segment and market as a whole
SNY - Book value capitalization of the company Sanofi
Sanofi's core assets are a global network of R&D centers and manufacturing sites, with strong positions in vaccines, rare diseases, and consumer healthcare. Its book value reflects this diversified foundation. The chart shows how the pharmaceutical giant manages its portfolio, investing in new, promising areas.
SNY - Share of the company's book capitalization Sanofi within the market segment - Pharma holding
Welltower is an investment fund that owns a vast healthcare real estate portfolio. The chart shows its stake in physical assets in this sector: hospitals, clinics, and nursing homes. The company provides physical infrastructure for healthcare.
Market segment balance sheet capitalization - Pharma holding
Sanofi is a classic European pharmaceutical giant. Its asset portfolio reflects its capital intensity. Sanofi invests in both R&D to create new drugs and a global network of manufacturing plants for vaccines and other therapeutics.
Book value of all companies included in the broad market index - GURU.Markets
Sanofi is a French pharmaceutical giant with strong positions in vaccines and rare disease treatments. Its balance sheet value comes from its global network of manufacturing sites, including Sanofi Pasteur, one of the world's largest vaccine producers, and its robust R&D centers.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Sanofi
Sanofi is a European pharmaceutical giant. Its moderate premium to its stock reflects both the strength of its current pipeline, particularly in immunology, and investor concerns about its ability to bring new blockbusters to market.
Market to book capitalization ratio in a market segment - Pharma holding
Sanofi is a French pharmaceutical company with a diversified portfolio including vaccines, rare disease treatments, and consumer products. This chart shows how the market assesses the stability of its business and the potential of its R&D pipeline to create future blockbusters, compared to its significant asset base.
Market to book capitalization ratio for the market as a whole
Sanofi is a French pharmaceutical company with a diversified portfolio, including drugs for rare diseases, diabetes, and vaccines. Against the backdrop of overall market trends, as illustrated by this chart, Sanofi's valuation reflects both the stability of its current business and investor expectations for its R&D.
Debts of the company, segment and market as a whole
SNY - Company debts Sanofi
For Sanofi, the French pharmaceutical giant, debt is a tool for financing the transformation of its product portfolio. The company uses debt for R&D and for biotech acquisitions to offset the loss of patents for old blockbusters. This chart shows how it is seeking new sources of growth.
Market segment debts - Pharma holding
Sanofi is a French pharmaceutical giant with a diversified drug portfolio. Like other industry players, Sanofi faces patent expirations and the need to expand its product line through R&D and acquisitions. Debt is used to finance these strategic moves. This chart illustrates the company's financial policy in the context of the pharmaceutical industry.
Market debt in general
Sanofi is a French pharmaceutical company with a diversified portfolio of drugs, vaccines, and consumer healthcare products. Like other industry players, Sanofi continually requires investment to expand its development pipeline. This total debt chart helps understand the financial environment in which the company makes decisions about R&D and acquisitions.
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Sanofi
Sanofi is a French pharmaceutical giant undergoing a transformation to strengthen its portfolio of innovative drugs. This chart shows how the company uses debt to finance R&D and biotech acquisitions. Debt is a tool for accelerating product innovation.
Market segment debt to market segment book capitalization - Pharma holding
Sanofi is a French pharmaceutical giant with a diversified portfolio of drugs, vaccines, and consumer healthcare products. This chart provides an assessment of the company's financial conservativeness. It compares its debt load to the overall market capitalization of the pharmaceutical industry, reflecting its balanced approach to growth.
Debt to book value of all companies in the market
Sanofi, the French pharmaceutical giant, has a diversified and stable business. This chart compares its financial policy with the overall market. It shows that the giant's debt burden is moderate compared to the average level of leverage across the economy, reflecting its balanced approach.
P/E of the company, segment and market as a whole
P/E - Sanofi
This chart for Sanofi, the French pharmaceutical giant, shows how the market perceives its dependence on key drugs. The company's P/E is heavily dependent on the success of its blockbuster drug, Dupixent. The metric's dynamics reflect investors' confidence in Sanofi's ability to diversify its revenue through new developments.
P/E of the market segment - Pharma holding
Sanofi is a French pharmaceutical company with a diversified portfolio of drugs, vaccines, and consumer healthcare products. The company focuses on breakthrough immunology products. This chart shows the average valuation for the European pharmaceutical industry. It allows investors to compare how Sanofi's scientific potential compares to its competitors.
P/E of the market as a whole
Sanofi is a French pharmaceutical company with a diversified portfolio, including drugs for rare diseases, vaccines, and consumer healthcare products. Its valuation, like that of other pharmaceutical giants, is determined by the success of its research pipeline. General market sentiment, reflected in this chart, is less important to Sanofi than clinical trial results.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Sanofi
Sanofi is a French pharmaceutical company with a diversified portfolio, including drugs for rare diseases, diabetes, and vaccines. This chart reflects investor expectations for its research potential. The valuation depends on sales forecasts for key drugs and the market's confidence in the success of its R&D strategy to create new blockbusters.
%20P%2FE%20Sanofi&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Sanofi&v=1772624016426 "Chart of the company's future (projected) P/E Sanofi")
Future (projected) P/E of the market segment - Pharma holding
Sanofi is a French pharmaceutical company with a diversified portfolio, including drugs for rare diseases, vaccines, and consumer healthcare products. This chart reflects the market's assessment of its stability. Comparing its earnings forecasts with the sector reveals how investors view its ability to generate sustainable income.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-holding&v=1772624016442 "Future (projected) P/E graph of the market segment - Pharma holding")
Future (projected) P/E of the market as a whole
Sanofi is a French pharmaceutical giant with a diversified portfolio, including drugs for rare diseases, vaccines, and consumer healthcare products. Like other large pharmaceutical companies, Sanofi prioritizes internal R&D success over overall market trends. However, this chart influences investors' overall assessment of the healthcare sector.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772624016532 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Sanofi
Sanofi is a French pharmaceutical company with a diversified portfolio of drugs, vaccines, and over-the-counter (OTC) products. Its profits depend on the success of its key products, particularly in immunology, and the results of its research pipeline. This chart shows how the company manages its portfolio to ensure stable growth.
Profit of companies in the market segment - Pharma holding
Sanofi is a French pharmaceutical company with a diversified portfolio of medicines, vaccines, and over-the-counter medications. The company is a global leader in vaccine production and treatment of rare diseases. Its financial performance reflects both stable demand for proven medications and success in developing new innovative drugs.
Overall market profit
Sanofi is a global pharmaceutical company headquartered in France, specializing in the development and production of medicines and vaccines. The company has strong positions in the treatment of rare diseases, diabetes, and vaccine production. Its financial results reflect both global healthcare needs and success in research and development of new drugs.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Sanofi
Sanofi is a French pharmaceutical company with a diversified drug portfolio. This chart reflects analyst expectations for its top-selling drug, Dupixent, as well as progress in developing new vaccines and drugs in other therapeutic areas to ensure long-term growth.
%20profit%20of%20the%20company%20Sanofi&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Sanofi&v=1772624016740 "Graph of future (projected) profit of the company Sanofi")
Future (predicted) profit of companies in the market segment - Pharma holding
Sanofi is a global French pharmaceutical company with a diversified portfolio, including drugs for rare diseases, diabetes, and vaccines. This chart reflects profitability forecasts for the entire pharmaceutical industry. It allows one to compare Sanofi's product pipeline with analysts' general expectations for the global healthcare market.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-holding&v=1772624016799 "Graph of future (predicted) profits of companies in a market segment - Pharma holding")
Future (predicted) profit of the market as a whole
French pharmaceutical giant Sanofi's profit forecast hinges on sales of its key drugs, particularly those treating rare diseases and inflammation, as well as vaccines. This chart reflects expectations for the company's product portfolio and its ability to bring new successful drugs to market to offset expiring patents.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772624016839 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Sanofi
Sanofi is a French pharmaceutical company with a diversified portfolio of drugs and vaccines. This chart shows how investors value its revenue, particularly in light of the success of Dupixent. The dynamics of the multiple reflect the market's confidence in its product portfolio and its ability to develop new blockbusters.
P/S market segment - Pharma holding
Sanofi is a global pharmaceutical company headquartered in France, specializing in drug development in areas such as immunology, rare diseases, and vaccines. This chart shows the average revenue estimate in the pharmaceutical industry. It helps assess how investors perceive Sanofi's research capabilities compared to its competitors.
P/S of the market as a whole
Sanofi is a French pharmaceutical company with a diversified portfolio, including drugs for rare diseases, vaccines, and consumer healthcare products. This chart, which displays Sanofi's average revenue estimates, helps understand how the market perceives its ability to generate growth through innovation in various healthcare areas.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Sanofi
Sanofi is a French pharmaceutical company with a diversified portfolio, including drugs for rare diseases, diabetes, and vaccines. The company's future revenue depends on the success of its blockbuster drug Dupixent and developments in its R&D pipeline. This chart reflects investor expectations for growth of its key drugs and the company's ability to develop new drugs.
%20P%2FS%20Sanofi&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Sanofi&v=1772624017006 "The graph of the company's future (projected) P/S Sanofi")
Future (projected) P/S of the market segment - Pharma holding
Sanofi is a French pharmaceutical company with a diversified portfolio including drugs for rare diseases, vaccines, and consumer healthcare products. This chart shows how the market views its strategy and R&D. Do investors believe in its ability to create new blockbusters to drive future growth?
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20holding&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-holding&v=1772624017085 "Future (projected) P/S market segment graph - Pharma holding")
Future (projected) P/S of the market as a whole
Sanofi is a French pharmaceutical giant with a diversified portfolio of drugs, vaccines, and consumer healthcare products. The company's success in developing new drugs, particularly in immunology, is essential to maintaining its growth. The stability of its business contributes to the overall positive expectations for the healthcare sector, as illustrated by this chart.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772624017134 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Sanofi
Sanofi is a French pharmaceutical company with a diversified portfolio, including drugs for rare diseases, diabetes, and vaccines. This chart shows the company's combined global sales of its drugs and vaccines, reflecting the needs of the global healthcare system.
Sales of companies in the market segment - Pharma holding
Sanofi is a French pharmaceutical giant with a diversified portfolio, including drugs for rare diseases, vaccines, and over-the-counter medications. The company focuses on innovation in immunology. This chart shows overall sales in the pharmaceutical sector, demonstrating the scale and competitive landscape of the market, in which Sanofi holds a strong position.
Overall market sales
Sanofi is a French pharmaceutical company, a global leader with a diversified portfolio of medicines, vaccines, and consumer healthcare products. This overall economic activity graph is indirectly important for Sanofi, as it is for other pharmaceutical industry players, as it determines the financial capacity of healthcare systems and consumers worldwide.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Sanofi
Sanofi is a French pharmaceutical company with a diversified portfolio, including drugs for rare diseases, vaccines, and over-the-counter medications. Future revenue depends on the success of its blockbuster drug Dupixent and developments in other areas. This chart reflects analysts' sales forecasts for key drugs and the potential of its research pipeline.
%20sales%20of%20the%20company%20Sanofi&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Sanofi&v=1772624017292 "Schedule of future (projected) sales of the company Sanofi")
Future (projected) sales of companies in the market segment - Pharma holding
Sanofi is a French pharmaceutical company, a global leader in vaccines and treatments for rare diseases, diabetes, and cardiovascular disease. This chart shows projected revenues for the entire pharmaceutical sector. It provides insight into overall healthcare spending trends, which is important for assessing Sanofi's portfolio.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-holding&v=1772624017328 "Schedule of future (projected) sales of companies in the market segment - Pharma holding")
Future (projected) sales of the market as a whole
Sanofi is a French pharmaceutical giant with a diversified portfolio, including drugs for rare diseases, diabetes, and vaccines. Demand for many of its products is not dependent on economic cycles. However, this chart is important for assessing the overall ability of global healthcare systems to finance procurement, particularly for innovative and expensive drugs, which are crucial to Sanofi's future growth.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772624017381 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Sanofi
Sanofi is a French pharmaceutical company with a diversified portfolio of drugs, vaccines, and consumer healthcare products. This chart illustrates the company's research and development efforts. The company's success depends on its ability to bring new drugs to market, particularly in areas such as immunology and rare diseases, to offset the expiration of old patents.
Market segment marginality - Pharma holding
Sanofi is a French pharmaceutical company with a diversified portfolio, including drugs for rare diseases, vaccines, and over-the-counter medications. This broad reach helps the company resist patent losses on individual products. This metric reflects how a balanced product line and global presence impact its operational efficiency.
Market marginality as a whole
Sanofi is a French pharmaceutical giant with a diversified portfolio of drugs, vaccines, and consumer healthcare products. This chart shows overall profitability. As such, Sanofi, like many large pharmaceutical companies, faces the challenge of patent expirations and the need to continually renew its portfolio through successful research and development.
Employees in the company, segment and market as a whole
Number of employees in the company Sanofi
Sanofi is a French pharmaceutical company with a diversified portfolio, including drugs for rare diseases, vaccines, and consumer products. This chart shows the global team. Headcount changes may reflect business restructuring, a focus on innovative drugs, and the spinoff or sale of lower-priority assets.
Share of the company's employees Sanofi within the market segment - Pharma holding
This chart demonstrates Sanofi's importance as a global leader in the pharmaceutical industry. Its significant share of employees in the sector reflects its diversified portfolio, which includes drugs for rare diseases, diabetes, and vaccines. This human capital supports a wide range of medical solutions for patients worldwide.
Number of employees in the market segment - Pharma holding
Sanofi is a French pharmaceutical company, a global leader in fields such as vaccines, rare diseases, and diabetes treatment. Drug development and production require a vast workforce of scientists, doctors, and manufacturing personnel. This chart illustrates the scale of the global pharmaceutical industry, of which Sanofi is a key employer.
Number of employees in the market as a whole
Sanofi is a French pharmaceutical giant. After several years of restructuring, the company has focused on breakthrough drugs, especially its blockbuster Dupixent (for the treatment of asthma and atopic dermatitis). This graph of total employment shows the state of payers. Sanofi's success depends on the ability of the healthcare system, financed by contributions from the working population, to pay for its expensive drugs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Sanofi (SNY)
Sanofi is a French pharmaceutical giant with a diversified portfolio of drugs and vaccines. Its ratio per employee reflects the value of its existing products and R&D pipeline. Its dynamics can indicate how the market perceives its ability to discover new blockbusters.
%20of%20the%20company%20Sanofi%20(SNY)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Sanofi-SNY&v=1772624017912 "Chart of market capitalization per employee (in thousands of dollars) of the company Sanofi (SNY)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma holding
Sanofi is a major European pharmaceutical giant with historical strength in vaccines and recent advances in immunology (Dupixent). Like its competitors, its value lies in its patents and R&D. This chart shows the market capitalization per employee, measuring the market's confidence in the company's research productivity.
%20by%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-holding&v=1772624017932 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma holding")
Market capitalization per employee (in thousands of dollars) for the overall market
Sanofi is a French pharmaceutical giant with a diversified portfolio of drugs and vaccines. This chart shows how the market values its R&D pipeline and existing products. The high valuation per employee is driven by the value of its intellectual property and the company's ability to bring new, successful drugs to market.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772624017955 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Sanofi (SNY)
Sanofi is a French pharmaceutical giant. The company is strong in areas such as vaccines, rare diseases, and consumer health. This chart shows the profitability of its diversified pharmaceutical portfolio. While Sanofi may not have the blockbusters of Merck, its stable vaccine and other drug businesses ensure a good return on R&D.
%20Chart%20Sanofi%20(SNY)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Sanofi-SNY&v=1772624017966 "Company Profit Per Employee (in thousands of dollars) Chart Sanofi (SNY)")
Profit per employee (in thousands of dollars) in the market segment - Pharma holding
Sanofi is a French pharmaceutical giant. This chart shows the average for the pharmaceutical industry. This sector thrives on R&D and patents. The average return on personnel is high here, as a single successful drug patent can generate billions, more than covering R&D costs and ensuring high profits per scientist.
%20in%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-holding&v=1772624018003 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma holding")
Profit per employee (in thousands of dollars) for the market as a whole
Sanofi is a French pharmaceutical company with a diversified portfolio of drugs, vaccines, and over-the-counter medications. Like other pharmaceutical giants, it seeks new blockbusters to drive growth. This chart evaluates employee performance at a major European pharmaceutical company operating in a competitive global market.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772624018043 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Sanofi (SNY)
Sanofi is a French pharmaceutical company with a diversified portfolio of drugs and vaccines. This chart shows its performance in the global pharmaceutical industry. The company's success and revenue per employee depend on the life cycle of its key drugs, patent expirations, and its ability to bring new successful drugs to market.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Sanofi-SNY&v=1772624018060 "Sales chart per company employee Sanofi (SNY)")
Sales per employee in the market segment - Pharma holding
Sanofi is a French pharmaceutical company with strong positions in vaccines, rare disease treatments, and immunology. This chart shows the average revenue per employee in this segment. It helps assess how productive their R&D and commercial divisions are in generating revenue compared to other European and American pharma giants.
Sales per employee for the market as a whole
Sanofi is a French pharmaceutical giant. Like other Big Pharma companies, their business depends on successful R&D and patents. Sanofi excels in vaccines, rare diseases, and immunology. This chart shows how much revenue their patented drug portfolio generates per team of researchers, manufacturers, and marketers.
Short shares by company, segment and market as a whole
Shares shorted by company Sanofi (SNY)
Sanofi is a French pharmaceutical company. The bearish sentiment seen on this chart is often associated with R&D setbacks. Investors may be disappointed by the lack of new blockbusters in the company's portfolio or fear competition that threatens its key drugs (for example, Dupixent).
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Sanofi-SNY&v=1772624018150 "Short Shares Chart for the Company Sanofi (SNY)")
Shares shorted by market segment - Pharma holding
Sanofi is a French pharmaceutical giant with strong positions in rare disease treatments, vaccines, and over-the-counter medications. This chart shows the overall sentiment around the sector. It reflects investors' collective bets that Big Pharma will face increased competition or regulatory pressure on drug prices.
Shares shorted by the overall market
Sanofi is a French pharmaceutical company with global reach, strong in vaccines and treatments for rare diseases. Like other healthcare giants, Sanofi is considered a defensive stock. This chart shows the aggregate level of bearish sentiment. When investors are fearful (the chart is rising), they often seek refuge in stocks with stable demand.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Sanofi (SNY)
Sanofi is a global pharmaceutical giant focused on immunology (Dupixent) and vaccines. This chart measures trend strength. "Overbought" (above 70) may indicate that investors are overly optimistic about Dupixent sales growth. "Oversold" (below 30) often reflects panic due to R&D failures or legal risks (as in the case of the Zantac lawsuit), which frighten investors.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Sanofi-SNY&v=1772624018292 "RSI 14 indicator chart for the company's stock Sanofi (SNY)")
RSI 14 Market Segment - Pharma holding
Sanofi (SNY) is a French pharmaceutical giant with a strong presence in vaccines and rare disease treatments, starring the blockbuster Dupixent. This metric measures the overall momentum of the Big Pharma sector. It helps us understand whether Sanofi's momentum is driven by R&D success or whether the company is simply following the industry's overall trend, which could be oversold due to patent collapses.
RSI 14 for the overall market
Sanofi is a French pharmaceutical giant with a diversified portfolio, ranging from vaccines to diabetes and rare disease treatments. Their business is inherently defensive. This chart, showing swings from euphoria to panic, has little impact on demand for their drugs. Investors often turn to Sanofi shares during times of market "panic," seeking stability.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SNY (Sanofi)
This chart shows how analysts value Sanofi. Their price targets are based on a single blockbuster drug, Dupixent (an asthma and eczema treatment), which is expected to offset the fading of old patents. The consensus forecast reflects whether Wall Street believes this single drug can drive the pharmaceutical giant's entire growth.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SNY-Sanofi&v=1772624018476 "A chart showing analyst consensus forecasts for the expected stock price. SNY (Sanofi)")
The difference between the consensus estimate and the actual stock price SNY (Sanofi)
Sanofi, the French pharmaceutical giant, is banking on its immunology blockbuster Dupixent and its strong vaccine division. The company is actively seeking new growth opportunities. This chart reflects analysts' confidence in their R&D pipeline and ability to diversify revenue. It shows the difference between the consensus price and the current valuation.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SNY-Sanofi&v=1772624018529 "A chart showing the difference between the consensus forecast and the actual stock price. SNY (Sanofi)")
Analyst consensus forecast for stock prices by market segment - Pharma holding
Sanofi is a French pharmaceutical giant whose sales are largely dependent on the blockbuster drug Dupixent (an asthma and eczema treatment). The company is seeking new growth drivers. This chart shows analyst consensus forecasts for the entire pharmaceutical sector. It reflects whether experts believe in the success of Big Pharma's R&D pipelines.
Analysts' consensus forecast for the overall market share price
Sanofi is a diversified European pharmaceutical giant. Like other big pharma companies, Sanofi is considered a relatively defensive asset. However, the overall market sentiment chart influences investor appetite. During periods of optimism, the market may prefer riskier biotechs, while in times of crisis, it may value Sanofi's stable cash flow and dividends.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Sanofi
Sanofi is a French pharmaceutical giant with strong positions in vaccines and immunology. The crown jewel of their portfolio is the blockbuster drug Dupixent (for the treatment of asthma and eczema). This chart reflects the market valuation of their key franchises. Their performance is heavily dependent on the growth rate of Dupixent, which should offset patent cliffs on other drugs.
AKIMA Market Segment Index - Pharma holding
Sanofi is a French pharmaceutical giant with a diversified portfolio including vaccines, rare disease treatments, and consumer products. This comprehensive index evaluates R&D. The chart shows the average value for the segment. This benchmark helps us understand how Sanofi's diversification and R&D pipeline differentiate it from the average pharmaceutical company.
The AKIM Index for the overall market
Sanofi is a French pharmaceutical giant with a diversified portfolio including diabetes treatments, rare disease medications, vaccines, and consumer products. This chart, which reflects the market average, provides macro context. It helps assess how Sanofi, which operates in the relatively defensive healthcare sector, stacks up against broader economic trends that impact investor sentiment and exchange rates.
